US · NEOG · MEDICAL - DIAGNOSTICS & RESEARCH
Neogen Corporation (NEOG) intrinsic value and stock valuation
$10.55as of 2026-11-21 · Mkt cap 2.49B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Neogen Corporation DCF and intrinsic value
InvestorsCraft values NEOG with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from NEOG’s statements →
Neogen Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Zenas BioPharma, Inc. (ZBIO) $23.85
- Novocure Ltd (NVCR) $10.71
- BioLife Solutions, Inc. (BLFS) $38.61
- CONMED Corporation (CNMD) $46.56
- Kestra Medical Technologies, Ltd. (KMTS) $25.10
- Azenta, Inc. (AZTA) $44.80
- Intellia Therapeutics, Inc. (NTLA) $10.00
- OPKO Health, Inc. (OPK) $1.57
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $870.4M | $894.7M | $924.2M | $822.5M | $527.2M |
| Operating income | -$-21.6M | $9.42M | $77.4M | $37.5M | $58.6M |
| Net income | -$-7.9M | -$-1.09B | -$-9.42M | -$-22.87M | $48.3M |
| EPSd | -$-36.32K | -$-5.03M | -$-43.51K | -$-121.08K | $447.2K |
| Operating cash flow | $83.2M | $58.2M | $35.3M | $41M | $68M |
| Capital expenditure | -$-51.3M | -$-104.59M | -$-111.42M | -$-65.76M | -$-24.43M |
| Free cash flow | $31.9M | -$-46.35M | -$-76.16M | -$-24.73M | $43.6M |
| Total assets | $3.35B | $3.44B | $4.55B | $4.55B | $992.9M |
| Total debt | $0.00 | $912.6M | $906.2M | $897.5M | $0.00 |
| Net debt | -$-185.5M | $783.6M | $735.6M | $734.3M | -$-44.47M |
| Total equity | $2.09B | $2.07B | $3.14B | $3.13B | $887.4M |
| Cash and short-term investments | $185.5M | $129M | $170.9M | $245.6M | $381.1M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $870.4M | $894.7M | $924.2M | $822.5M | $527.2M |
| Cost of revenue | $461.9M | $473.3M | $461.6M | $416.5M | $284.2M |
| Gross profit | $408.5M | $421.4M | $462.6M | $406M | $243M |
| Research and development expenses | $18.4M | $21.1M | $22.5M | $26M | $17.1M |
| Selling, general and administrative expenses | $411.7M | $402M | $382.8M | $342.4M | $167.4M |
| Other expenses | $0.00 | -$-9.04M | -$-20.03M | $0.00 | $0.00 |
| Operating expenses | $430.1M | $412M | $385.2M | $368.4M | $184.4M |
| Cost and expenses | $892M | $885.2M | $846.8M | $784.9M | $468.5M |
| Interest income | $0.00 | $3.11M | $6.36M | $3.17M | $1.34M |
| Interest expense | $57.6M | $71.6M | $73.4M | $56M | $70K |
| Depreciation and amortization | $121.9M | $125.7M | $121.2M | $88.4M | $23.7M |
| Ebitda | $170.5M | -$-937.75M | $182.6M | $122.3M | $83.9M |
| Operating income | -$-21.6M | $9.42M | $77.4M | $37.5M | $58.6M |
| Total other income/expenses, net | $12.6M | -$-1.14B | -$-91.73M | -$-59.56M | $1.59M |
| Income before tax | -$-9M | -$-1.13B | -$-14.3M | -$-22.04M | $60.2M |
| Income tax expense | -$-1.1M | -$-41.07M | -$-4.88M | $830K | $11.9M |
| Net income | -$-7.9M | -$-1.09B | -$-9.42M | -$-22.87M | $48.3M |
| Weighted average shares outstanding | $217.5M | $216.9M | $216.5M | $188.9M | $107.7M |
| Weighted average diluted shares outstanding | $217.5M | $216.9M | $216.5M | $188.9M | $108M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $185.5M | $129M | $170.9M | $245.6M | $381.1M |
| Net receivables | $146.8M | $153.4M | $173M | $153.3M | $99.7M |
| Inventory | $144.3M | $190.9M | $189.3M | $133.8M | $122.3M |
| Total current assets | $604.6M | $576.9M | $589.2M | $585.9M | $626.8M |
| Property, plant and equipment, net | $497M | $356.3M | $291.9M | $198.8M | $110.6M |
| Goodwill and intangible assets | $2.37B | $2.48B | $3.65B | $3.74B | $250.2M |
| Long-term investments | $0.00 | $0.00 | $230K | $0.00 | $0.00 |
| Total non-current assets | $2.74B | $2.87B | $3.96B | $3.97B | $366.1M |
| Total assets | $3.35B | $3.44B | $4.55B | $4.55B | $992.9M |
| Accounts payable | $79.1M | $79.6M | $83.1M | $76.7M | $34.6M |
| Short-term debt | $0.00 | $27.4M | $9.99M | $6.55M | $0.00 |
| Deferred revenue | $3.6M | $5.56M | $4.63M | $4.62M | $5.46M |
| Total current liabilities | $158.2M | $174M | $154.3M | $145.5M | $77.8M |
| Long-term debt | $0.00 | $887.7M | $898.7M | $894.3M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.09B | $1.2B | $1.25B | $1.27B | $27.7M |
| Capital lease obligations | $0.00 | $20.9M | $17.9M | $12.1M | $0.00 |
| Total liabilities | $1.25B | $1.37B | $1.4B | $1.42B | $105.6M |
| Common stock | $34.8M | $34.7M | $34.7M | $34.6M | $17.3M |
| Retained earnings | -$-544.3M | -$-536.42M | $555.6M | $565M | $587.9M |
| Accumulated other comprehensive income (loss) | -$-13.6M | -$-28.9M | -$-30.02M | -$-33.25M | -$-27.77M |
| Total equity | $2.09B | $2.07B | $3.14B | $3.13B | $887.4M |
| Total investments | $0.00 | $0.00 | $550K | $82.3M | $336.6M |
| Total debt | $0.00 | $912.6M | $906.2M | $897.5M | $0.00 |
| Net debt | -$-185.5M | $783.6M | $735.6M | $734.3M | -$-44.47M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | -$-7.9M | -$-1.09B | -$-9.42M | -$-22.87M | $48.3M |
| Depreciation and amortization | $116.3M | $125.7M | $121.2M | $90.5M | $24.1M |
| Stock-based compensation | $13.4M | $17.3M | $13.8M | $10.2M | $7.15M |
| Change in working capital | $58.8M | -$-5.93M | -$-72.68M | -$-24.2M | -$-4.42M |
| Accounts receivable | $6.8M | $11.6M | -$-20.1M | -$-53.88M | -$-7.8M |
| Inventory | $38.2M | -$-16.12M | -$-55.95M | $9.96M | -$-21.07M |
| Accounts payable | $19.8M | -$-400K | $13.8M | $18.6M | $20.2M |
| Net cash provided by operating activities | $83.2M | $58.2M | $35.3M | $41M | $68M |
| Investments in property, plant and equipment | -$-51.3M | -$-104.59M | -$-111.42M | -$-65.76M | -$-24.43M |
| Acquisitions, net | $0.00 | $5.08M | $110K | $12.6M | -$-38.74M |
| Net cash used for investing activities | $70.5M | -$-99.19M | -$-29.31M | $201M | -$-97.23M |
| Common stock issued | $1.6M | $2.24M | $2.46M | $1.2M | $7.93M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-99.4M | -$-1.6M | $1.92M | -$-118.08M | $6.81M |
| Net change in cash | $56.5M | -$-41.61M | $7.37M | $118.8M | -$-31.13M |
| Cash at end of period | $185.5M | $129M | $170.6M | $163.2M | $44.5M |
| Operating cash flow | $83.2M | $58.2M | $35.3M | $41M | $68M |
| Capital expenditure | -$-51.3M | -$-104.59M | -$-111.42M | -$-65.76M | -$-24.43M |
| Free cash flow | $31.9M | -$-46.35M | -$-76.16M | -$-24.73M | $43.6M |
Line items
Line items
Line items
About Neogen Corporation
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
- CEO
- Mikhael Nassif
- Employees
- 2.97K
- Beta
- 1.79
Included in
Explore
Frequently asked questions
What is the intrinsic value of Neogen Corporation (NEOG)?
Neogen Corporation (NEOG) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NEOG undervalued?
NEOG trades at a price of $10.55 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.